The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1748
February 16, 2026
View Complete Issue         Table of Contents 2019 
Sebetralstat (Ekterly) for Treatment of Hereditary Angioedema Attacks
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Sebetralstat (Ekterly) for Treatment of Hereditary Angioedema Attacks
February 16, 2026 (Issue: 1748)
Sebetralstat (Ekterly – Kalvista), an oral plasma kallikrein inhibitor, has been approved by the FDA for treatment of acute hereditary angioedema (HAE) attacks in patients ≥12 years old. It is the first oral drug to be approved in the US for...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Sebetralstat (Ekterly) for Treatment of Hereditary Angioedema Attacks
Article code: 1748c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.